Navigation Links
Amsterdam Molecular Therapeutics Reports Half Year Results 2009
Date:8/12/2009

AMSTERDAM, August 13 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today reported its results for the first half year of 2009.

    Highlights

    - Start of the preregistration clinical trial with Glybera(R)
      in Canada following two previous clinical trials
    - Presentation of additional data indicating that Glybera(R) offers
      a clinically important health benefit, accomplished by a significant
      and clinically important reduction in the incidence of acute
      pancreatitis in patients
    - Significant progress in research and development for other
      pipeline projects including hemophilia B, Duchenne muscular dystrophy
      and Parkinson's disease
    - Key financial figures in line with guidance
    - Cash & cash equivalents of EUR 25 million at June 30, 2009

Results comparison

AMT's key financial figures are well within the budgets for the first semester and therefore remain in line with the guidance that the company has given for 2009. The operating loss increased to EUR 9.9 million for the six months ended June 30, 2009, from EUR 9.1 million for the same period in 2008. This difference is primarily due to the increase of research & development costs to EUR 7.1 million from EUR 5.8 million in the same period of 2008. This increase is particularly related to the clinical development and regulatory work on the company's lead product, Glybera(R), as well as increased staffing for this and other programs. General and administrative costs decreased to EUR 2.9 million, from EUR 3.3 million in the first half of 2008, primarily as a result of decreased advisor's fees.

The net loss for the half of 2009 was EUR 9.4 million, as compared to a net loss of EUR 8.1 million for the first half of 2008.

At June 30, 2009, AMT's cash and cash equivalents amounted to E
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Amsterdam Molecular Therapeutics Reports Full Year Results 2008
2. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
3. Amsterdam Molecular Therapeutics Part of Next Biotech Index
4. Amsterdam Molecular Therapeutics to Appoint George Morstyn to Supervisory Board
5. Amsterdam Molecular Therapeutics to Appoint Alexander Ribbink to Supervisory Board
6. Amsterdam Molecular Therapeutics Reports Full Year Results 2007
7. Amsterdam Molecular Therapeutics to Appoint Philippe van Holle (Celgene) to Supervisory Board
8. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
9. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
10. SAFC Supply Solutions(R) Announces Raw Materials Line Developed Specifically to Meet Molecular Diagnostics Manufacturing Requirements
11. Sorenson Molecular Genealogy Foundation to Protect Archived DNA Using Biomatricas Room Temperature Storage
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2014)... 2014 The Europe Thermal Protective ... to provide crucial revenue forecasts. It estimates the ... at a CAGR of 7.5%, from 2013 to ... Europe Thermal Protective Clothing market report for a ... supported by various tables and figures. , ...
(Date:11/27/2014)... Nov. 27, 2014 Research and ... "Global Palmitic Acid Industry Report 2014" report to ... The Global Palmitic Acid Industry Report 2014 ... state of the global palmitic acid industry. ... including definitions, classifications, applications and industry chain structure. The ...
(Date:11/27/2014)... 2014 Spartan Bioscience today announced that ... Drug Safety (MFDS) regulatory approval for its Spartan ... in less than 60 minutes from a non-invasive cheek ... aid for doctors to determine therapeutic strategies for drugs ... some of the world’s most commonly prescribed drugs such ...
(Date:11/27/2014)... November 27, 2014 First ...   Elsevier , a world-leading provider ... is pleased to announce the launch of a new ... The launch of Extreme Mechanics ... at the forefront of applied sciences such as micro ...
Breaking Biology Technology:The Europe Thermal Protective Clothing market is estimated to grow up to $577.9 million by 2018 - Report by MicroMarket Monitor 2The Europe Thermal Protective Clothing market is estimated to grow up to $577.9 million by 2018 - Report by MicroMarket Monitor 3Global Palmitic Acid Industry Report 2014 2Spartan Bioscience Receives Korean Regulatory Approval for First Rapid DNA Test of Mutations Affecting Metabolism of Common Drugs 2Spartan Bioscience Receives Korean Regulatory Approval for First Rapid DNA Test of Mutations Affecting Metabolism of Common Drugs 3Elsevier Announces the Launch of a New Journal: Extreme Mechanics Letters 2Elsevier Announces the Launch of a New Journal: Extreme Mechanics Letters 3
... 4, 2011 InterMune, Inc. (NASDAQ: ITMN ) ... President of InterMune, will present at the Bank of America ... on May 11, 2011, at 1:00 p.m. PDT.   ... investors and other interested parties may log on to the ...
... a letter from Nicusa Capital urging BioClinica (Nasdaq: BIOC ... from incumbent Directors Berg, Olukotun, Parker and Weinstein on 2011 Proxy: ... Chairman of the Board BioClinica, Inc. 826 Newtown-Yardley Rd. Newtown, PA ... of BioClinica: As of May 4, 2011, Nicusa owns ...
... Inc. (Nasdaq: NXTM ), a leading manufacturer ... the first quarter of 2011 ended March  31, 2011, ... guidance range. (Logo: http://photos.prnewswire.com/prnh/20110503/MM94799LOGO) Net ... to a record $50.6 million compared with revenue of ...
Cached Biology Technology:This is a Letter From Nicusa Capital Urging BioClinica Shareholders to Vote AGAINST Proxy Proposal 2 and WITHHOLD Votes From Incumbent Directors Berg, Olukotun, Parker and Weinstein on 2011 Proxy 2This is a Letter From Nicusa Capital Urging BioClinica Shareholders to Vote AGAINST Proxy Proposal 2 and WITHHOLD Votes From Incumbent Directors Berg, Olukotun, Parker and Weinstein on 2011 Proxy 3This is a Letter From Nicusa Capital Urging BioClinica Shareholders to Vote AGAINST Proxy Proposal 2 and WITHHOLD Votes From Incumbent Directors Berg, Olukotun, Parker and Weinstein on 2011 Proxy 4This is a Letter From Nicusa Capital Urging BioClinica Shareholders to Vote AGAINST Proxy Proposal 2 and WITHHOLD Votes From Incumbent Directors Berg, Olukotun, Parker and Weinstein on 2011 Proxy 5NxStage® Reports Record Revenue for the First Quarter of Fiscal 2011 2NxStage® Reports Record Revenue for the First Quarter of Fiscal 2011 3NxStage® Reports Record Revenue for the First Quarter of Fiscal 2011 4NxStage® Reports Record Revenue for the First Quarter of Fiscal 2011 5NxStage® Reports Record Revenue for the First Quarter of Fiscal 2011 6NxStage® Reports Record Revenue for the First Quarter of Fiscal 2011 7
(Date:11/4/2014)... LAKE CITY, Nov. 5, 2014 – University of Utah ... enzymes to help jet fuel produce electricity without needing ... be used to power portable electronics, off-grid power and ... online today in the American Chemical Society journal ... electricity through a chemical reaction between a fuel and ...
(Date:11/4/2014)...   3D scanner developer targets ... Fuel3D , a developer of 3D scanning solutions, today announced ... (£4 million). This funding builds on the company,s initial $2.6 ... the way for the commercial launch of the company,s consumer ... led by Chimera Partners and will be used to ramp-up ...
(Date:11/3/2014)... LOS ANGELES , Nov. 3, 2014 /PRNewswire/ ... California -based life sciences company focused on ... eTNS system for the treatment of neurological ... Institute of Industrial Property has issued a Notice ... The patent application is co-owned by NeuroSigma and ...
Breaking Biology News(10 mins):Jet-fueled electricity at room temperature 2Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3
... (June 21, 2012) Autism Speaks, the world,s leading ... of new research grants totaling nearly $2.9 million in ... extraordinarily proud of Autism Speaks, not only for funding ... avenues to understanding autism," said Autism Speaks Co-founder Bob ...
... ocean infrastructure development to tap energy sources such as ... pile driving, the practice of pounding long, hollow steel ... energy turbines and other structures. But pile driving creates ... marine animals., Many scientists and regulators have assumed that ...
... world are preparing to address the urgent need to ... biodiversity. The Global Biodiversity Informatics Conference (GBIC) will ... and policy in Copenhagen, Denmark from 2-4 July. ... strategy and roadmap to make best use of the ...
Cached Biology News:Autism Speaks awards nearly $2.9 million to fund autism research 2Autism Speaks awards nearly $2.9 million to fund autism research 3Autism Speaks awards nearly $2.9 million to fund autism research 4Turning down the dial: Ocean energy development with less sound 2Turning down the dial: Ocean energy development with less sound 3Turning down the dial: Ocean energy development with less sound 4A new vision for harnessing data about life on Earth 2
... genetically engineered Klenow polymerase in which the 3 ... only the 5 to 3 polymerase activity. The ... the enzyme of choice for isotopic or biotin ... method, and for DNA sequencing by the Sanger ...
... a DNA-dependent RNA polymerase which is stringently ... efficiently synthesizes in vitro transcripts from almost ... a T7 promoter. Transcripts can be ... vitro translation, substrates in RNA processing systems, ...
... overproducer ATP: D-hexose 6- phosphotransferase/D-glucose-6-phosphate: ... unit of HK will phosphorylate ... 1 min at 25C at ... G6P-DH will oxidize 1 mol ...
Goat polyclonal to Haptoglobin ( Abpromise for all tested applications). Antigen: Affinity purified human haptoglobin. Entrez GeneID: 3240 Swiss Protein ID: P00738...
Biology Products: